The global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market garnered a market value of USD 2.54 billion in 2022. The market is expected to accumulate a market value of USD 3.5 billion by 2023, and will eventually reach USD 6.82 billion by registering a CAGR of 6.9% in the forecast period 2023 to 2033.
The growth of the chimeric antigen receptor (CAR) T-Cell therapy market can be attributed to technological advancements and demand for personalized medicines. The market for chimeric antigen receptor (CAR) T-Cell therapy registered a CAGR of 7% in the historical period 2018 to 2022.
Chimeric Antigen Receptor (CAR) T-cell therapy is a type of cancer treatment that uses a patient's own immune system to fight cancer. It is a type of immunotherapy that involves modifying a patient's T cells (a type of white blood cell) to recognize and attack cancer cells.
The CAR T-cell therapy process involves collecting a patient's T cells, genetically modifying them to express a CAR on their surface, and then reinfusing the modified cells back into the patient's bloodstream. The CAR is designed to recognize and bind to a specific protein on the surface of cancer cells, which triggers the T cells to attack and destroy the cancer cells.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 3.5 billion |
| Anticipated Forecast Value (2033) | USD 6.82 billion |
| Projected Growth Rate (2023 to 2033) | 6.9% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
According to market research and competitive intelligence provider Future Market Insights- the market for Chimeric antigen receptor (CAR) T-Cell therapy reflected a value CAGR of 7% during the historical period, 2018 to 2022.
The growth of the market can be attributed to several factors, including the increasing prevalence of cancer, the growing demand for personalized and targeted therapies, and the increasing investments in research and development of CAR T-cell therapies.
In addition, the approval of several CAR T-cell therapies by regulatory agencies, such as the US FDA, has also boosted market growth.
Several companies are actively involved in the development and commercialization of CAR T-cell therapies, including Novartis, Gilead Sciences, Kite Pharma, and bluebird bio.
These companies have launched several CAR T-cell therapy products, such as Kymriah, Yescarta, and Tecartus, which have shown promising results in clinical trials and have received regulatory approval for the treatment of various types of blood cancers.
Thus, the market for Chimeric antigen receptor (CAR) T-cell therapy is expected to register a CAGR of 6.9% in the forecast period 2023 to 2033.
Growing demand for personalized and targeted therapies boosting the market growth
The increasing incidence of cancer worldwide is a major driver of the CAR T-cell therapy market. According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, with an estimated 9.6 Billion deaths in 2018.
CAR T-cell therapy has shown high success rates in clinical trials for the treatment of certain types of blood cancers, such as leukemia and lymphoma. The therapy has demonstrated durable responses and has shown the potential to cure some patients.
CAR T-cell therapy is a personalized and targeted therapy that is tailored to a patient's individual immune system and cancer cells. This approach has gained popularity in recent years as it can result in better outcomes and fewer side effects compared to traditional cancer treatments.
Several biotechnology and pharmaceutical companies are investing heavily in the research and development of CAR T-cell therapies. This has resulted in the development of innovative therapies and the expansion of the CAR T-cell therapy market.
The approval of CAR T-cell therapy products by regulatory agencies, such as the US FDA, has boosted market growth. Regulatory approval provides credibility to CAR T-cell therapy products, which can increase patient and physician acceptance of these therapies.
Active and continuous research and development driving CAR T- cell therapy market growth
CAR T-cell therapy has shown promising results in treating certain types of blood cancers, such as leukemia and lymphoma. However, it is a complex and expensive treatment that requires specialized medical centers with the expertise to perform it.
The therapy can also cause severe side effects, including cytokine release syndrome and neurotoxicity, which require careful monitoring and management.
Several companies are actively involved in the development and commercialization of CAR T-cell therapies, including Novartis, Gilead Sciences, Kite Pharma, and bluebird bio.
These companies have launched several CAR T-cell therapy products, such as Kymriah, Yescarta, and Tecartus, which have shown promising results in clinical trials and have received regulatory approval for the treatment of various types of blood cancers.
The high cost of therapy along with limited availability creates obstacles to market growth
CAR T-cell therapy is a highly expensive treatment due to its complex manufacturing process and personalized nature. The high cost can limit patient access to therapy and can also impact healthcare system budgets.
CAR T-cell therapy requires specialized medical centers with the expertise to perform the treatment, which can limit patient access to the therapy. Additionally, the therapy is only approved for the treatment of certain types of blood cancers, which limits its applicability to other cancer types.
CAR T-cell therapy can cause severe side effects, including cytokine release syndrome and neurotoxicity, which can be life-threatening. These side effects require careful monitoring and management, which can add to the overall cost of the therapy.
As the demand for CAR T-cell therapy grows, there is a shortage of manufacturing capacity to produce the therapy at scale. This shortage can limit the availability of the therapy and can also impact the cost of the therapy.
The regulatory approval process for CAR T-cell therapy can be challenging and time-consuming. The regulatory agencies require extensive clinical data to support the safety and efficacy of the therapy, which can delay the approval process and increase the overall cost of development.
Availability of advanced healthcare infrastructure shaping landscape for (CAR) T-Cell therapy
North America is a significant market for Chimeric Antigen Receptor (CAR) T-Cell Therapy, with the USA being the largest market in the region.
Several factors are driving the growth of the CAR T-cell therapy market in North America, including the high prevalence of cancer, the increasing demand for personalized and targeted therapies, and the availability of advanced healthcare infrastructure.
In addition, several biotechnology and pharmaceutical companies in the region are actively involved in the research and development of CAR T-cell therapies, which is driving the growth of the market.
The USA is a key market for CAR T-cell therapy, with several CAR T-cell therapy products approved for the treatment of various types of blood cancers, such as Kymriah, Yescarta, and Breyanzi.
The high cost of CAR T-cell therapy in the USA remains a challenge for the market, as it can limit patient access to the therapy. However, initiatives to improve insurance coverage and patient access to CAR T-cell therapy are underway, which is expected to support the growth of the market in the coming years.
Thus, North America is expected to possess a 45% market share for (CAR) T-Cell Therapy in 2023.
Increasing demand for effective cancer treatments driving the growth of (the CAR) T-Cell market in Europe
Several factors are driving the growth of the CAR T-cell therapy market in Europe, including the increasing prevalence of cancer, the demand for personalized and targeted therapies, and the availability of advanced healthcare infrastructure.
In addition, several biotechnology and pharmaceutical companies in Europe are actively involved in the research and development of CAR T-cell therapies, which is driving the growth of the market.
Several CAR T-cell therapy products have been approved for the treatment of various types of blood cancers in Europe, including Kymriah and Yescarta.
The high cost of CAR T-cell therapy remains a challenge for the market in Europe, as it can limit patient access to the therapy. However, initiatives to improve patient access to CAR T-cell therapy are underway, which is expected to support the growth of the market in the coming years.
The European Medicines Agency (EMA) has established a framework for the approval of CAR T-cell therapy products, which is expected to streamline the regulatory process in the future.
Overall, the Europe CAR T-cell therapy market is expected to continue to grow in the coming years, driven by the increasing demand for effective cancer treatments and the development of innovative CAR T-cell therapy products. Thus, Europe is expected to possess a 39% market share for (CAR) T-Cell Therapy in 2023.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
High rate of positive response contributing to increasing use of (CAR) T-Cell Therapy market
Yescarta is a type of CAR T-cell therapy that involves collecting a patient's T-cells and genetically modifying them in a laboratory to express a chimeric antigen receptor (CAR) that targets a protein called CD19, which is found on the surface of B-cells, including the cancerous B-cells that cause NHL.
The modified T-cells are then infused back into the patient, where they seek out and destroy the cancer cells.
Yescarta has been shown to be effective in clinical trials, with high rates of complete response and durable remissions in patients with relapsed or refractory NHL.
It is approved by the FDA for use in adults with certain types of NHL and is considered a promising option for patients who have exhausted other treatment options. Thus, by type, Yescarta is expected to possess a 45% market share for (CAR) T-Cell Therapy in 2023.
Key players in the chimeric antigen receptor (CAR) T-Cell therapy market are Abbott Laboratories, Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Fresenius SE & Co. KGaA, Johnson & Johnson, Medtronic PLC, Novartis AG, Endo International PLC, and Pfizer Inc.
Abbott Laboratories has contributed to CAR T-cell therapy by providing diagnostic tools to help identify patients who are suitable candidates for this treatment. For example, Abbott's Vysis CLL FISH Probe Kit is a diagnostic test that can be used to detect genetic abnormalities in chronic lymphocytic leukemia (CLL), a type of cancer that can be treated with CAR T-cell therapy.
This test helps identify patients who have certain genetic mutations that make them more likely to respond to CAR T-cell therapy.
Baxter has contributed to CAR T-cell therapy by providing cell culture media and other materials needed for the manufacturing of CAR T-cell therapies.
Baxter's Cell Culture Media and supplements are used in the laboratory to grow and expand the T-cells that will be used for CAR T-cell therapy. The company has also developed a closed system for the production of CAR T-cell therapies, which can help minimize contamination and improve the efficiency of the manufacturing process.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 3.5 billion |
| Market Value in 2033 | USD 6.82 billion |
| Growth Rate | CAGR of 6.9% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Type, Application, End User, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | United States of America, Canada, Brazil, Mexico, Germany, United Kingdom, Spain, Germany, Italy, China, Japan, India, South Korea, South Africa, GCC Countries |
| Key Companies Profiled | Abbott Laboratories; Baxter International Inc.; Becton, Dickinson, and Company; Boston Scientific Corporation; Fresenius SE & Co. KGaA; Johnson & Johnson; Medtronic PLC; Novartis AG; Endo International PLC; Pfizer Inc. |
| Customization | Available Upon Request |
The market is valued at USD 3.5 billion in 2023.
Abbott Laboratories, Baxter International Inc., and Becton, Dickinson, and Company are the leading industry participants.
The market is expected to reach USD 6.82 billion by 2033.
Rise in cancer cases is propelling the market's growth and development.
The yescarta segment is likely to remain preferred until 2033.
Explore Therapy Area Insights
View Reports
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
